In line with this, the availability of eNOS, oxidative modifications of the aorta and platelet adhesion/activation (Figure 7a–d) were normalised, suggesting the inhibitory effects of apocynin treatment may offer long‐term protection against vascular oxidative stress and endothelial dysfunction. The gene discussed is NOS3; the disease is endothelial dysfunction.